Canine parvovirus (CPV) is a contagious virus that causes enteric disease in all dog populations. CPV capsid protein, VP2, plays important roles for virus infection and host immune response. To develop vaccine against CPV, the gene encoding for VP2 protein was cloned and expressed in baculovirus/insect cell expression system. The recombinant VP2 protein was successfully expressed and detected in the baculovirus infected insect cells by Western blot analysis, using antibody specific to CPV VP2 protein. It was found that the recombinant VP2 protein can self-assemble into virus like particles (VLPs) with the size range from 50-100 nm as revealed by transmission electron microscope. The VP2-VLPs were also shown to have hemagglutination activity, similar to CPV, when incubated with goose erythrocytes. This VP2-VLPs were used for syringe and needle-free, oral vaccine development. Non-viral delivery agents, bacterium like particles (BLPs) derived from non-living Lactococcus lactis, known for their safety and efficiency for mucosal immune stimulation, were selected for the oral vaccine formulation. After ad-mix method, VP2-VLPs bound to BLPs was detected with immunofluorescent assay. This oral vaccine will be further investigated for its immune stimulation efficiency.